|
| | Preview | Issue Date | Title | Author(s) |
| 1 | | 5-Aug-2024 | Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study | Yeung, David T; Shanmuganathan, Naranie; Reynolds, John; Branford, Susan; Walia, Mannu; Yong, Agnes Sm; Shortt, Jake; Chee, Lynette; Viiala, Nicholas; Cunningham, Ilona; Ross, David M; D'Souza, Alwyn Bernard; Wright, Matthew; Harrup, Rosemary Anne; Forsyth, Cecily ; Filshie, Robin; Lane, Steven W; Browett, Peter J; Grove, Carolyn S; Grigg, Andrew A; Hughes, Timothy P |
| 2 | | 1-Mar-2024 | Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria | Kulasekararaj, Austin G; Lehtinen, Anna-Elina; Forsyth, Cecily ; Gandhi, Shreyans; Griffin, Morag; Körper, Sixten; Mikala, Gabor; Muus, Petra; Overgaard, Ulrik; Patriquin, Christopher J; Pullon, Humphrey; Shen, Yu-Min; Spearing, Ruth; Szer, Jeff; De la Borderie, Guillemette; Duda, Petra W; Farzaneh-Far, Ramin; Ragunathan, Sharan; Sayegh, Camil E; Vadysirisack, Douangsone D; Schrezenmeier, Hubert |
| 3 | | 22-Nov-2023 | Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry | Ng, Wei Yang; Erber, Wendy N; Grigg, Andrew; Dunne, Karin; Perkins, Andrew; Forsyth, Cecily ; Ross, David M |
| 4 | | 5-Jul-2023 | Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants | Homan, Claire C; Drazer, Michael W; Yu, Kai; Lawrence, David Michael; Feng, Jinghua; Arriola-Martinez, Luis Alberto; Pozsgai, Matthew J; McNeely, Kelsey E; Ha, Thuong Thi; Venugopal, Parvathy; Arts, Peer; King-Smith, Sarah; Cheah, Jesse Jc; Armstrong, Mark; Wang, Paul; Bödör, Csaba; Cantor, Alan B; Cazzola, Mario; Degelman, Erin S; DiNardo, Courtney D; Duployez, Nicolas; Favier, Rémi; Fröhling, Stefan; Rio-Machin, Ana; Klco, Jeffery M; Krämer, Alwin; Kurokawa, Mineo; Lee, Joanne; Malcovati, Luca; Morgan, Neil V; Georges, Natsoulis; Owen, Carolyn; Patel, Keyur P; Preudhomme, Claude; Raslova, Hana; Rienhoff, Hugh Young; Ripperger, Tim; Schulte, Rachael R; Tawana, Kiran; Velloso, Elvira; Benedict, Yan; Kim, Erika Mijin Kwon; Sood, Raman; Hsu, Amy P; Holland, Steven M; Phillips, Kerry; Poplawski, Nicola; Babic, Milena; Wei, Andrew H; Forsyth, Cecily J ; Mar Fan, Helen; Lewis, Ian; Cooney, Julian P; Susman, Rachel; Fox, Lucy C; Blombery, Piers; Singhal, Deepak; Hiwase, Devendra K; Phipson, Belinda; Schreiber, Andreas W; Hahn, Christopher N; Scott, Hamish S; Liu, Paul P; Godley, Lucy A; Brown, Anna L |
| 5 | | 20-Dec-2022 | Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry | Nguyen, James; Wellard, Cameron; Chung, Eliza; Cheah, Chan Y; Dickinson, Michael; Doo, Nicole Wong; Keane, Colm; Talaulikar, Dipti; Berkahn, Leanne; Morgan, Susan; Hamad, Nada; Cochrane, Tara; Johnston, Anna M; Forsyth, Cecily J ; Opat, Stephen; Barraclough, Allison; Mutsando, Howard; Ratnasingam, Sumita; Giri, Pratyush; Wood, Erica M; McQuilten, Zoe K; Hawkes, Eliza A |
| 6 | | 14-Jun-2022 | Paraprotein associated heparin resistance during cardiopulmonary bypass | Khuong, Jacqueline N; Forsyth, Cecily J ; Manuel, Lucy; Kingsford-Smith, Kate; Srivastava, Arpit; Bassin, Levi |
| 7 | | Jul-2021 | Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: A case report | Rogers, James ; Forsyth, Cecily J ; Ford, Tom ; Mikhail, Philopatir |
| 8 | | Oct-2020 | Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product | Forsyth, Cecily J ; Niederwieser, D.; Hamm, C.; Cobb, P.; Mo, M.; Tucci, A.; Hanes, V.; Delwail, V.; Hajek, R.; Chien, D. |
| 9 | | Apr-2020 | Cutaneous multiple myeloma | Forsyth, Cecily J ; Jagger, Jacqueline ; Lai, S. |
| 10 | | Feb-2020 | Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss | Forsyth, Cecily J ; Venugopal, P.; Gagliardi, L.; Feng, J.; Phillips, K.; Babic, M.; Poplawski, N.K.; Rienhoff, H.Y.,Jr.; Schreiber, A.W.; Hahn, C.N.; Brown, A.L.; Scott, H.S. |
| 11 | | Sep-2019 | Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation | Forsyth, Cecily J ; Joshi, M.; Taper, J.; Rowlings, P.; Campbell, P.; Crispin, P.; Harvey, M.; Underhill, C.; Bayley, A.; Byth, K.; Huang, G.; Hertzberg, M. |
| 12 | | Apr-2019 | Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014 | Forsyth, Cecily J ; Baade, P.D.; Ross, D.M.; Anderson, L.A.; Fritschi, L. |
| 13 | | Apr-2019 | The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia | Forsyth, Cecily J ; Minson, A.G.; Cummins, K.; Fox, L.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A. |
| 14 | | Jan-2019 | Hereditary haemorrhagic telangiectasia | Forsyth, Cecily J ; Mangkorntongsakul, Varitsara |
| 15 | | Dec-2018 | The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications | Forsyth, Cecily J ; Melville, K.; Tiley, Campbell |
| 16 | | Nov-2018 | Recommendations for the use of pegylated interferon-alpha in the treatment of classical myeloproliferative neoplasms | Forsyth, Cecily J ; Chan, Wai-Hoong ; Grigg, A.; Cook, N.C.; Lane, S.W.; Burbury, K.; Perkins, A.C.; Ross, D.M. |
| 17 | | Aug-2018 | Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features | Forsyth, Cecily J ; Godfrey, A.L.; Campbell, P.J.; MacLean, C.; Buck, G.; Cook, J.; Temple, J.; Wilkins, B.S.; Wheatley, K.; Nangalia, J.; Grinfeld, J.; McMullin, M.F.; Kiladjian, J.J.; Green, A.R.; Harrison, C.N. |
| 18 | | Apr-2018 | Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia | Forsyth, Cecily J ; Crassini, K.R.; Zhang, E.; Balendran, S.; Freeman, J.A.; Best, O.G.; Mackinlay, N.J.; Han, P.; Stevenson, W.S.; Mulligan, S.P. |
| 19 | | Jan-2018 | Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses | Forsyth, Cecily J ; Harrison; Balendran, S.; Harrison, A.; Morel-Kopp, M. C.; Ward, C. |
| 20 | | May-2017 | Raccoon eyes in systemic light chain amyloidosis | Forsyth, Cecily J ; Tiley, Campbell |
| 21 | | May-2017 | The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia | Forsyth, Cecily J ; Fox, L.; Cummins, K.D.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A. |
| 22 | | May-2017 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study | Forsyth, Cecily J ; Quach, H.; Fernyhough, L.; Henderson, R.; Corbett, G.; Baker, B.; Browett, P.; Blacklock, H.; Underhill, C.; Cannell, P.; Trotman, J.; Neylon, A.; Harrison, S.; Link, E.; Swern, A.; Cowan, L.; Dimopoulos, M.A.; Miles Prince, H. |
| 23 | | Mar-2017 | A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis | Forsyth, Cecily J ; Ho, P.J.; Bajel, A.; Burbury, K.; Dunlop, L.; Durrant, S.; Perkins, A.C.; Ross, D.M. |
| 24 | | Feb-2017 | Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. | Forsyth, Cecily J ; Agarwal, R.; Blombery, P.; McBean, M.; Jones, K.; Fellowes, A.; Doig, K.; Westerman, D.A. |
| 25 | | Jan-2017 | Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea | Forsyth, Cecily J ; Douglas, G.; Harrison, C.N.; Bennett, M.; Stevenson, W.S.; Hounsell, J.; Ratnasingam, S.; Ritchie, D.; Ross, D.M.; Grigg, A. |
| 26 | | Aug-2016 | Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort | Forsyth, Cecily J ; Campbell, P.J.; MacLean, C.; Beer, P.A.; Buck, G.; Wheatley, K.; Kiladjian, J.J.; Harrison, C.N.; Green, A.R. |
| 27 | | Apr-2016 | Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms | Forsyth, Cecily J ; Malherbe, J.A.; Fuller, K.A.; Mirzai, B.; Kavanagh, S.; So, C.C.; Ip, H.W.; Guo, B.B.; Howman, R.; Erber, W.N. |
| 28 | | Oct-2015 | The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway | Forsyth, Cecily J ; Best, O.G.; Singh, N.; Mulligan, S.P. |
| 29 | | Feb-2015 | The oral iron chelator deferasirox inhibits NF-kappaB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia | Forsyth, Cecily J ; Banerjee, A.; Mifsud, N. A.; Bird, R.; Szer, J.; Tam, C.; Kellner, S.; Grigg, A.; Motum, P.; Bentley, M.; Opat, S.; Grigoriadis, G. |
| 30 | | Feb-2015 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. | Yeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.L.; Trotman, J.; Forsyth, Cecily J ; Taper, J.; Ross, D.M.; Beresford, J.; Tam, C.; Mills, A.K.; Grigg, A.; Hughes, T. |
| 31 | | Jul-2014 | Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy | Forsyth, Cecily J ; Paidas, M.J.; Quere, I.; Rodger, M. |
| 32 | | May-2014 | Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea | Forsyth, Cecily J ; Verner, E.; Grigg, A. |
| 33 | | Aug-2013 | A multicenter, open-label, noncomparative screening study of Enzastaurin in adult patients with Non-Hodgkin Lymphomas | Forsyth, Cecily J ; Gomez-Almaguer, D.; Camargo, J.F.C.; Eliadis, P.E.; Crespo-Solis, E.; Pereira, J.; Gutierrez-Aguirre, C.H.; Rivaz-Vera, S.; Roberson, S.; Lin, B.; Smith, N.V.; Hamid, O. |
| 34 | | Jan-2013 | Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia | Forsyth, Cecily J ; Freeman, J.A.; Crassini, K.R.; Best, O.G.; Mackinlay, N.J.; Han, P.; Stevenson, W.S.; Mulligan, S.P. |
| 35 | | Jul-2012 | The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease | Forsyth, Cecily J ; Best, O.G.; Che, Y; Singh, N.; Christopherson, R.I.; Mulligan, S.P. |
| 36 | | Apr-2012 | When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? | Forsyth, Cecily J ; Bird, R.; Kenealy, M.; Wellwood, J.; Leahy, M.F.; Seymour, J.F.; To, L.B. |
| 37 | | Feb-2012 | Distinguishing types 1 and 2M von Willebrand disease | Forsyth, Cecily J ; Favaloro, E.J.; Koutts, J. |
| 38 | | Aug-2011 | Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants | Forsyth, Cecily J ; Trotman, J.; Fournier, M; Lamy, T.; Seymour, J.F.; Sonet, A.; Janikova, A.; Shpilberg, O.; Gyan, E.; Tilly, H.; Estell, J.; Decaudin, D.; Fabiani, B.; Gabarre, J.; Salles, B.; Van Den Neste, E.; Canioni, D.; Garin, E.; Fulham, M.; Vander Borght, T.; Salles, G. |
| 39 | | Dec-2001 | Collection and transport of samples for laboratory testing in von Willebrand's disease (VWD): time for a reappraisal? | Forsyth, Cecily J ; Favaloro, E.J.; Nair, S.C. |
| 40 | | Oct-2001 | Abnormal dicentric chromosome with co-amplification of sequences from chromosomes 11 and 19: a novel rearrangement in a patient with myelodysplastic syndrome transforming to acute myeloid leukemia | Forsyth, Cecily J ; Smith, A.; Heaps, L.S.; Sharma, P.; Jarvis, A. |
| 41 | | Feb-1999 | Hodgkin's disease: a GP's guide to diagnosis and management | Forsyth, Cecily J |
| 42 | | May-1997 | Management of acute vascular graft thrombosis associated with HIT syndrome: a case report | Forsyth, Cecily J ; Wilson, M.; McGahan, T.; White, G. |
| 43 | | Sep-1996 | Rapid quantitation of mixed red cell populations using flow cytometry | Forsyth, Cecily J ; Nelson, M.; Popp, H.; Gibson, J. |
| 44 | | Mar-1996 | Autologous red cell recovery and relapse of multiple myeloma after bone marrow transplantation: is this a graft-versus-myeloma effect? | Forsyth, Cecily J ; Nelson, M.; Popp, H.; Snowdon, L.; Gibson, J.; Joshua, D. |
| 45 | | Feb-1996 | Thalidomide responsive chronic pulmonary GVHD | Forsyth, Cecily J ; Cremer, P.D.; Torzillo, P.; Iland, H.J.; Young, G.A. |
| 46 | | 1996 | A quick differentiation between iron deficiency and thalassaemia syndrome | Forsyth, Cecily J ; Yuen, S.; Brown, R.; Zarkos, K. |
| 47 | | Oct-1995 | Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men | Forsyth, Cecily J ; Adams, M.R.; Jessup, W.; Robinson, J.; Celermajer, D.S. |
| 48 | | Mar-1995 | Severe hemolysis due to anti-D in a D-negative recipient of an orthotopic liver transplant | Forsyth, Cecily J ; Popp, H.; Kronenberg, H.; McCaughan, G. |
| 49 | | Feb-1995 | First trimester antigen typing of fetal red cells using a flow cytometric technique | Forsyth, Cecily J ; Nelson, M.; Popp, H.; Peat, B.; Boogert, A.; Gibson, J. |
| 50 | | 1995 | Transfusion of patients with haemoglobinopathies | Forsyth, Cecily J ; Chisholm, J.; Popp, H. |
| 51 | | 1995 | Quantifying the loss of ABO antigenicity in a patient with acute myeloid leukemia by flow cytometric analysis | Forsyth, Cecily J ; Popp, H.J.; Nelson, M.; Falson, M.; Kronenberg, H. |
| 52 | | Dec-1994 | Rapid detection of Rh(D)- or K-positive fetal red cells in chorion villus samples by a flow cytometric technique | Forsyth, Cecily J ; Nelson, M.; Popp, H.; Gibson, J. |
| 53 | | 1994 | Development of a flow cytometric test for the detection of D-positive fetal cells after fetomaternal hemorrhage and a survey of the prevalence in D-negative women | Forsyth, Cecily J ; Nelson, M.; Popp, H.; Horky, K.; Gibson, J. |
| 54 | | Nov-1992 | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron | Forsyth, Cecily J ; Coates, A.S.; Childs, A.; Cox, K.; Joshua, D.E.; McNeil, E.; Grygiel, J.J. |
Loading...
2
0
20
0
false